综合门德尔随机化和多组分析确定与心血管疾病风险相关的抗过敏药物标
Huilin Lian1, Dai Li2,3, Youjie Zeng4
1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
某些抗过敏药物可能会增加心血管疾病 (CVD) 的风险. 预尼松与心血管药物的使用增加了不良事件,这表明临床药物治疗需要谨慎.
科学领域:
- 药物基因组学
- 心血管研究
- 药物安全
背景情况:
- 心血管疾病 (CVD) 构成了全球重大健康挑战.
- 了解药物诱导的风险对于有效的药物治疗至关重要.
研究的目的:
- 研究抗过敏药物标与心血管疾病风险之间的关联.
- 评估抗过敏药物的心血管安全性,包括普德尼松.
主要方法:
- 对抗过敏药物标和心血管疾病队列 (CAD,HF,MI,AF) 的孟德尔随机化 (MR) 分析.
- 敏感性分析,转录组学,丰富分析,分子对接和FAERS数据库审查.
- 对与心血管药物联合使用的普德尼松进行药监测分析.
主要成果:
- 有11种抗过敏药物与心血管疾病有显著联系.
- 普雷德尼松和洛拉塔丁与心血管疾病风险增加有关; 扎菲尔卢卡斯特显示风险降低.
- 与心血管药物一起使用的普雷尼松增加了心血管不良结果.
结论:
- 某些抗过敏药物,如普德尼松,可能会增加心血管疾病的风险.
- 发现建议在处方抗过敏药物时谨慎使用,特别是在已有心血管疾病的患者中.
- 可能的机制包括中性粒细胞外陷和脂质积累.
更多相关视频
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
相关概念视频
Allergic Drug Reactions
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Factors Affecting Drug Response: Overview
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
